2024 Clag-m/i方案治疗儿童复发/难治急性髓系白血病的临床疗效和安全性分析

Clag-m/i方案治疗儿童复发/难治急性髓系白血病的临床疗效和安全性分析

Author: pjjc

August undefined, 2024

WebAug 4, 2024 · Two previous PALG studies have confirmed that the CLAG-M regimen (a combination of cladribine, Ara-C, G-CSF and mitoxantrone) has high efficacy and low toxicity in refractory/relapsed AML patients. This salvage regimen was particularly effective in a very poor-risk subgroup with primary refractoriness, early relapse or relapse after stem cell ... WebNov 6, 2024 · Title: Lintuzumab Ac-225 in Combination with CLAG-M Chemotherapy in Relapsed/Refractory AML: Interim Results of a Phase I Study. Key Highlights: 83% of patients (5/6) receiving 0.50 uCi/kg of ...

Leukemia Treatment Regimens: Acute Myeloid Leukemia (AML)

WebJul 1, 2016 · Wrzesień-Kuś等应用CLAG方案治疗难治复发AML, 1年无病生存（DFS）率仅为29%，与我们的研究结果相似。Wrzesień-Kuś等在此后的研究中改用CLAG-M方案，1年DFS率为68.6%。本组病例中，有1例CLAG方案化疗获得CR后复发的深度治疗患者，更换CLAG-M方案后再次获得CR。 WebThe CLAG regimen is highly active in patients with relapsed and/or refractory acute myeloid leukemia (AML). We administered CLAG-based chemotherapy to 20 previously … is synesthesia a mental illness

CLAG方案治疗复发、难治急性髓系白血病疗效、安全性分析及随访

http://www.qk.sjtu.edu.cn/jimcp/CN/Y2024/V14/I02/116 WebApr 1, 2024 · [The efficacy and safety of CLAG-M/I regimen for relapsed or refractory acute myeloid leukemia in children]. 1 Europe PMC requires Javascript to function … WebHere, we conducted a case-control study in these patients to compare the efficacy of CLAG-M induction (28 patients) versus standard 3+7 induction chemotherapy (24 patients). Response rates (P=0.014) and median overall survival (P=0.025) were 64% and 202 days (95% CI 37-367 days) versus 29% and 86 days (95% CI 36-136) in the CLAG-M and 3+7 ... if then excel string

A Phase I Study of Lintuzumab Ac225 in Combination with CLAG-M ...

CLAG-based induction therapy in previously untreated high risk …

WebThe efficacy and safety of CLAG-M/I regimen for relapsed or refractory acute myeloid leukemia in children. 儿童复发/难治急性髓系白血病（AML）往往对一线治疗药物耐药， … WebCLAG方案和FLAG方案治疗难治或复发性急性髓系白血病对比观察. 罗文丰余惠兰邹兴立倪勋魏锦. 【摘要】：目的比较克拉屈滨联合阿糖胞苷和粒细胞集落刺激因子 (G-CSF)的 … if then exhibit smithsonianhttp://www.qk.sjtu.edu.cn/jimcp/CN/Y2024/V14/I02/116 ifthenexp

"WebJun 14, 2024 · 100% and 95%. Compared to 186 medically matched adults treated with CLAG-M alone, CLAG-M/GO3 was associated with better survival in patients with favorable-risk disease. These data indicate that CLAG-M/GO3 is safe and more efﬁcacious than CLAG-M alone in favorable-risk AML/high-grade myeloid neoplasm. " - Clag-m/i方案治疗儿童复发/难治急性髓系白血病的临床疗效和安全性分析

Clag-m/i方案治疗儿童复发/难治急性髓系白血病的临床疗效和安全性分析

WebCLAG方案和FLAG方案治疗难治或复发性急性髓系白血病对比观察. 摘要：目的比较克拉屈滨联合阿糖胞苷和粒细胞集落刺激因子 (G-CSF)的化疗方案 (CLAG方案)和氟达拉滨联合 … WebIn case of partial remission, a second CLAG-M was administered. Patients in complete remission (CR) received consolidation courses based on high-dose Ara-C and MIT with or without 2-CdA. Forty-three patients from five centers were registered: 25 primary resistant and 18 relapsed. CR was achieved in 21 (49%) patients, 20 (47%) were refractory ...

Did you know?

Web摘要：目的:观察CLAG方案(克拉屈滨+阿糖胞苷+粒细胞集落刺激因子)治疗难治、复发急性髓系白血病(acute myeloid leukemia,AML)的疗效、安全性和不良反应。方法 :回顾性分析2015年7月至2024年1月我院收治的使用CLAG方案±地西他滨治疗的7例难治、复发AML患者,观察其疗效和不良反应,并进行随访。 WebFeb 26, 2024 · Notably, 71% of patients receiving Actimab-A with CLAG-M achieved MRD or minimal residual disease negative status. The combination also had a clinically acceptable safety profile. The goal of this ...

WebMethods This study was a retrospective analysis of patients with relapsed/refractory AML who received treatment with CLAG or CLAG-M (cladribine 5 mg/m2 intravenously [IV] … WebMay 2, 2024 · One such regimen is CLAG-M (Cladribine, Cytarabine, Mitoxantrone, G-CSF) that has been frequently used at our center. However, it is difficult to predict which patients are likely to respond to CLAG-M or experience treatment-related toxicities. In patients with newly diagnosed AML, studies have demonstrated that achievement of minimal residual ...

WebThe CLAG regimen consisting of continuous intravenous infusion of cladribine shows high CR in the treatment of AML patients, but the duration of CR is short, myelosuppression is … Web使用clag-m/i方案1个疗程后，6例患儿cr；1例患儿pr，接受了第2个疗程治疗，并最终获得cr；7例cr患儿后续均进行了allo-hsct。截至末次随访时间，7例患儿处于CR状态，例8 …

Web【摘要】：目的:观察CLAG方案(克拉屈滨+阿糖胞苷+粒细胞集落刺激因子)治疗难治、复发急性髓系白血病(acute myeloid leukemia,AML)的疗效、安全性和不良反应。方法 :回顾性 …

WebCladribine is used to treat hairy cell leukemia, chronic lymphocytic leukemia (CLL), non-Hodgkin's lymphomas. Cladribine is administered by infusion through a vein. The … if then excel multiple sheetsWebCLAG-M/I方案具体包括：克拉屈滨5 mg/m 2 ，静脉滴注（静滴）2 h，第1~5天；阿糖胞苷1 g/m 2 ，静滴，第1~5天；G-CSF 5 μg/kg，皮下注射，第0~5天（以化疗前1天为第0天）；米托蒽醌或伊达比星8 mg/m 2 ，静滴，第1~3天。研究后期由于米托蒽醌无法供应，我们用伊 … if then excel sumWebDec 3, 2015 · The CLAG regimen (G-CSF 300 mcg sc, cladribine 5 mg/m 2 over 2 hours, and cytarabine 2 gm/m 2 over 4 hours beginning 2 hours after cladribine, all daily times 5 … is synesthesia autismWebDec 12, 2024 · This phase II trial studies how well CPX-351 or the CLAG-M regimen (consisting of the drugs cladribine, cytarabine, G-CSF, and mitoxantrone) works in treating medically less-fit patients with acute myeloid leukemia or other high-grade myeloid neoplasms. Drugs used in chemotherapy, such as CPX-351, cladribine, cytarabine, G … is synesthesia geneticWebNov 4, 2024 · NEW YORK, Nov. 4, 2024 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) ("Actinium") today announced that 100% of evaluable patients in the third and planned final dose cohort of the Actimab-A CLAG-M Phase 1 trial being conducted at the Medical College of Wisconsin (MCW) achieved remission. Across all … is synesthesia neurodivergentWebDec 3, 2015 · CLAG±M (cladribine, cytarabine, granulocyte colony stimulating factor ± mitoxantrone) Results in High Response Rates in Older Patients with Secondary and … if then excel range of valuesWebThe combination of cladribine/Ara‐C/granulocyte‐colony stimulating factor and mitoxantrone (CLAG‐M) shown promising results in adult R/R‐AML. We aim to … if then excel statement with text